Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105956 | 0.88 | CYP4F2 (0.47) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL12984187 | 0.85 | CYP4F2 (0.45) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL3623961 | 0.85 | CYP4F2 (0.45) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL1745188 | 0.84 | TAAR1 (0.53) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL2431502 | 0.83 | KDM4E (0.50) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL25240413 | 0.83 | CYP4F2 (0.43) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL16048081 | 0.81 | KDM4E (0.44) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL29056374 | 0.81 | CYP4F2 (0.47) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL2556229 | 0.81 | CYP4F2 (0.53) | KDM4EHPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL435614 | 0.80 | CHRNA7 (0.55) | KDM4EHPGDHSD17B10ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| EP-3409671-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3114123-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| CN-106414434-A | Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes | 詹森药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-3114123-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2970161-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015134039-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-11 | — | — | WO | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1731505-A1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1698624-A1 | PHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | KDM4E 3412/4885HPGD 2069/4885HSD17B10 1592/4885 |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | GPR119, FFAR1, GPR55 | KDM4E 2755/4885HPGD 2081/4885HSD17B10 449/4885 |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | KDM4E 3412/4885HPGD 2069/4885HSD17B10 1592/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | KDM4E 3200/4885HPGD 3421/4885HSD17B10 1683/4885 |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | GPR119, GPR55, FFAR1 | KDM4E 2731/4885HPGD 1868/4885HSD17B10 328/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | KDM4E 3412/4885HPGD 2069/4885HSD17B10 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.